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Background: Unintended pregnancy is a complex phenomenon which raise to take an emergency decision. Low
contraceptive prevalence and high user failure rates are the leading causes of this unexpected situation. High user
failure rates suggest the vital role of emergency contraception to prevent unplanned pregnancy. Levonorgestrel - a
commonly used progestin for emergency contraception. However, little is known about its pharmacokinetics and
optimal dose for use. Hence, there is a need to conduct a systematic review of the available evidences.
Methods: Randomized, double-blind trials were sought, evaluating healthy women with regular menstrual cycles, who
requested emergency contraception within 72 h of unprotected coitus, to one of three regimens: 1.5 mg single dose
levonorgestrel, two doses of 0.75 mg levonorgestrel given 12 h apart or two doses of 0.75 mg levonorgestrel given 24 h
apart. The primary outcome was unintended pregnancy; other outcomes were side-effects and timing of next
menstruation.
Results: Every trial under consideration successfully established the contraceptive effectiveness of levonorgestrel for
preventing unintended pregnancy. Moreover, a single dose of levonorgestrel 1.5 mg for emergency contraception
supports its safety and efficacy profile. If two doses of levonorgestrel 0.75 mg are intended for administration, the second
dose can positively be taken 12–24 h after the first dose without compromising its contraceptive efficacy. The main side
effect was frequent menstrual irregularities. No serious adverse events were reported.
Conclusions: The review shows that, emergency contraceptive regimen of single-dose levonorgestrel is not inferior in
efficacy to the two-dose regimen. All the regimens studied were very efficacious for emergency contraception and
prevented a high proportion of pregnancies if taken within 72 h of unprotected coitus. Single levonorgestrel dose
(1.5 mg) can substitute two 0.75 mg doses 12 or 24 h apart. With either regimen, the earlier the treatment is given, the
more effective it seems to be.
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Access to emergency contraception and its need for in-
creasing awareness and convenience is very important
nowadays. Post-coital or emergency contraception is a
simple, reliable and effective strategy. However, the com-
plications associated with the emergency contraception
are needed to be addressed before its full potential is re-
alized. The most challenging aspect is that healthcare
personnel and potential users are both quite ignorant of
this approach [1]. The other major obstacle which pre-
vents the extensive use of emergency contraception is
that both potential users and doctors believe that such
approaches to contraception are accompanied with fre-
quent and severe side-effects [2-4]. Previous data suggest
that, the significance of emergency contraceptive pills
cannot be ignored any longer, since one million abor-
tions and two million unwanted pregnancies could be
prevented in the U.S. each year if its widespread use
could be ensured [5].
Currently available commonly acknowledged hormonal
method of post-coital contraception was first described by
Yuzpe and Lancee [6] and Yuzpe et al. [7]. Based on the
findings of these authors, each dosage included the com-
bination of 200 μg ethinyl oestradiol and 2 mg dl-norgestrel
given in two divided doses where the second dose was
given after 12 h of the first dose, within 72 h of unprotected
intercourse. Though the pregnancy rate was only 1.6%,
there was a relatively high prevalence of side-effects (~50%
of cases). Side effects including nausea and/or vomiting,
this leads to decreased compliance of patients [8]. Even
though the Yuzpe regimen has become an established and
recommended method of emergency contraception, there
is a need to reduce the incidence of adverse effects while
maintaining effectiveness [9].
Levonorgestrel (LNG) is a synthetic, biologically active
progestogen, structurally related to 19-nortestosterone,
which may be used alone or in combination with estro-
gens for the prevention of unintended pregnancies fol-
lowing unprotected coitus [10]. LNG is only sought as a
supportive method for irregular rather than regular use
and LNG is intended to be used immediately after inter-
course but prior to pregnancy has become recognized
[11]. LNG is also safe and effective in women with type I
and type II diabetes [12]. Levonorgestrel-only emergency
contraceptive has an efficiency rate of 89% if it is used
correctly within 72 h after unprotected intercourse.
LNG also diminishes the risk of pregnancy, following a
single act of mid-cycle unprotected sexual intercourse,
from 8% on average, to 1.1% [13]. Every time the dose is
delayed 12 h after starting emergency contraception
treatment it reduces efficacy by about 50% [14].
LNG works in several different mechanisms depending
on the cycle day of unprotected intercourse and the day on
which the treatment is started. LNG may inhibit theprocess of ovulation, fertilization or implantation [15-20].
However, there is no direct clinical indication that supports
these mechanisms. Emergency contraception is effective
only before a fertilized egg is implanted because it can’t dis-
rupt an existing pregnancy, i.e., emergency contraceptives
are not abortifacient [21]. Several studies suggested that the
lowest concentration required to prevent ovulation is
0.48 nmol/L [22]. Hence, appropriate dosing is critical to
ensure the prevention of pregnancy.
For emergency contraception, there is pharmacoki-
netic evidence for two doses of 0.75 mg of levonorges-
trel, 12 h apart [23-25]. The oral bioavailability of
levonorgestrel is > 90%. However, this has been reported
to depend on the dosage form and to be affected by a
concomitant administration of estrogens [26,27]. The
peak concentration after a single oral dose of 0.75 mg of
levonorgestrel is attained within 1 h after administration,
with a half-life that is within 20 to 60 h [23-25]. How-
ever, not much is known about the pharmacokinetics of
a single dose of 1.5 mg of levonorgestrel in fertile
women during the periovulatory period of the menstrual
cycle [23].
The purpose of this study was to compare the efficacy
and side-effects of two treatments, when administered up
to 72 h after unprotected coitus: a single dose of 1.5 mg
levonorgestrel; and two separate doses of 0.75 mg levonor-
gestrel that are given 12 and 24 h apart. The main out-
comes were pregnancy rates, proportions of pregnancies
prevented, side-effects and timing of the first menstrual
period after treatment. We also thought to analyze the ef-
fect of treatment delay on the efficacy of contraception.
Our idea was that all the regimens in consideration
would have similar efficacy in preventing pregnancy. We
also analyzed how the timing of contraception in rela-
tion to coitus influenced treatment effectiveness.
Methods
Criteria for inclusion and exclusion
Randomized, double blind studies were selected for this
review. The literature which included women of fertile
age, compared one and/or two doses of levonorgestrel
taken in different regimens and described the kinetics or
dynamics of the drug were also reviewed. Reasons for
exclusion including non-English studies, literatures in-
volving non-human models, studies which compared
levonorgestrel with other emergency hormonal contra-
ceptives and publications concerned with dosage forms
other than oral tablets.
Data sources
MEDLINE, HighWire Press, Elsevier, PubMed, Google
Scholar, Springerlink, EBSCO, and Wolters Kluwer Health
databases were searched from 1967–2012 using the key
terms emergency contraception, postcoital contraception,
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double dose. The trials identified with our search strategy
were initially checked for duplicates and relevance for the
review by looking at the titles and abstracts. If it was not
possible to exclude a publication by looking at the title or
the abstract, the full paper was retrieved. Decisions on
which trials to include were independently made by two re-
viewers. Bibliographies of retrieved articles for additional
studies were also searched. We limited the search to
English-language reports involving humans. Studies were
selected where patient outcomes or pharmacokinetics were
assessed with alternative levonorgestrel-only emergency
contraception (EC).
Data extraction
Two authors independently reviewed the search results for
reports of studies of any design of hormonal drugs taken
orally for contraception, immediately before or after each
act of intercourse during one or more menstrual cycles. We
found 114 relevant studies (Figure 1). We excluded eighty
one trials from our review because they contained incom-
plete information on the drug regimen, number of preg-
nancies, or the duration of data collection and four because
only a partial report or abstract was available. Of the
remaining 29 studies, 14 provided data on regimens con-
taining levonorgestrel. The others described studies com-
paring with other compounds and therefore those ten
studies were omitted from this review. Discrepancies were
resolved by discussion and consultation with other re-
viewers including clinicians if needed.Figure 1 Study selection flow diagram.Outcome measures
Outcome measures included pregnancy rates, percent of
pregnancies prevented and side-effects. From kinetic
viewpoint, the area under the plasma concentration ver-
sus time curve to last time, area under the plasma con-
centration curve to infinity, peak plasma concentration,
time of peak plasma concentration, elimination rate con-
stant and terminal half-life were observed. We also
assessed the outcome by comparing the length of the
cycle, bleeding patterns, follicular rupture and ovulation
period, ovulatory dysfunction, length of luteal phase, day
of maximal luteal serum progesterone (P4), follicular
outcome, luteal serum glycodelin and the effect on total
lutenizing hormone (LH).
Finally, we used the Preferred Reporting Items for Sys-
tematic reviews and Meta-Analyses (PRISMA) criteria
for reporting systematic reviews of studies that evaluate
healthcare interventions, a quality appraisal tool.Results
Six of the 14 trials were randomized, double blind studies
of a single regimen. Eight trials included multiple groups of
women given levonorgestrel tablets of different doses. The
method of treatment allocation was not described, so we
considered each group as a separate case series. The total
number of treatment groups analyzed across all studies was
28. Of these groups, 11 evaluated tablets containing
0.75 mg levonorgestrel, and the others evaluated tablets
containing other doses (Table 1).
Table 1 Study design and demographic data







Type of trial Dose Dose frequency
Arowojolu et al., (2002)
[30]
Nigeria 1160 19-35 Prospective comparative study 0.75 mg &
1.5 mg
Once & two split doses 12 h apart
Croxatto et al., (2004) [33] Chile, Dominican
Republic
58 18-40 Two-center, randomized, double-blind, placebo-controlled study 0.75 mg Two doses given 12 h apart, or a single dose




Two doses, 12 h apart vs. a single dose
Durand et al., (2001) [18] Mexico 45 29-35 Randomized, comparative study 0.75 mg Two doses taken 12 h apart, at 0 h & after
48 h
Durand et al., (2005) [34] Mexico 30 29-35 Randomized, comparative study 0.75 mg Two doses taken 12 h apart, at 0 h & after
48 h
Gainer et al., (2007) [28] Chile 12 18-32 — 1.5 mg Once
Hapangama et al., (2001)
[19]
Scotland 12 26-41 Prospective, randomized, double-blind, crossover study 0.75 mg Two doses given 12 h apart
Johansson et al., (2002)
[23]
Dominican Republic 5 18-45 Randomized, comparative study 0.75 mg &
1.5 mg
Once, two doses given 12 h apart, two doses
given 24 h apart
Kook et al., (2002) [24] USA 16 19-44 Open label study 0.75 mg Twice, taken 12 h apart
Ngai et al., (2005) [32] China 2071 20-34 Double-blind, randomized trial 0.75 mg Every 24 h & every 12 h
Noé et al., (2010) [35] Chile 388 18-38 Prospective, open-label, single-drug, single dose, uncontrolled
clinical trial
1.5 mg Once
Raymond et al., (2006) [36] USA 120 18-38 Case-series study 1.5 mg Once
Sambol et al., (2006) [29] USA 22 13-16 Prospective, single-period, single center, open-label clinical trial 0.75 mg Once
Tremblay et al., (2001) [25] South Africa 24 18-26 Open, observer-blind, randomized study 0.75 mg Once, two doses given 12 h apart, two doses




















Shohel et al. BMC Women's Health 2014, 14:54 Page 5 of 10
http://www.biomedcentral.com/1472-6874/14/54Levonorgestrel has a prolonged half-life of around
24.4 h. This rationalizes considering single-dose LNG
emergency contraception as well as two doses taken 12–
24 h apart. Pharmacokinetics of levonorgestrel was eval-
uated in a study using different dosing strategies in
young, healthy, women [25]. This trial involved 24
women who were randomized to three levonorgestrel
treatment groups: a single 0.75 mg dose, two 0.75 mg
doses taken 12 h apart and two 0.75 mg doses taken
24 h apart. The pharmacokinetic profiles were similar
with all three treatments. Plasma concentrations of levo-
norgestrel were 9.6 ± 0.38 nmol/L at 12 h and 6.2 ± 0.53
nmol/L at 24 h after the first 0.75 mg dose. Effective
concentrations greater than 0.48 nmol/L were main-
tained for 48–60 h after the 12 and 24 h doses. The
statistical investigations indicated no significant differ-
ences between groups in any of the pharmacokinetic pa-
rameters i.e. peak plasma concentration (Cmax), time to
reach peak plasma concentration (tmax), elimination rate
constant (Kel), half-life (t1/2) and area under plasma
concentration-time curve AUC.
An investigation on the pharmacokinetics of 1.5 mg
levonorgestrel in lactating women was also evaluated
[28]. Twelve healthy breastfeeding participants received
1.5 mg of LNG. For 72 h after dosing, the women
abstained from nursing and fed their infants with milk
which was frozen previously. Sequential milk and blood
samples were collected and assessed for LNG and sex
hormone binding globulin for 120 h. LNG concentra-
tions peaked in milk and plasma in 2-4 h and 1-4 h after
dosing, respectively. Concentrations in milk were similar
to those in plasma but were consistently lower. Projected
infant exposure to LNG is 1.6 mg on the day of dosing,
0.3 mg on the second day and 0.2 mg on the third day.
Another study examined plasma LNG concentrations
and pharmacokinetics after oral administration of a sin-
gle 0.75 mg tablet [24]. Blood samples were collected se-
quentially over 72 h after dosing in a fasting state. Cmax
of LNG was 14.1 ± 7.9 ng/mL and tmax was 1.63 ± 0.74 h.
Plasma concentration of LNG vs. time profiles were sub-
jected to noncompartmental pharmacokinetic analysis
for determining half-lives, apparent oral clearances (Cl/
F), apparent volumes of distribution after oral adminis-
tration (V/F) and mean residence time (MRT). The half-
lives ranged from 16.2 h to 32.3 h (mean = 24.4 ± 5.3 h).
The Cl/F was 7.06 ± 2.69 L/h, V/F was 260 ± 129 L and
MRT was 27.8 ± 5.2 h.
In a different study, the pharmacokinetics of levonorges-
trel between female adolescents and adults were compared
[29]. A total of 259 levonorgestrel plasma concentrations in
22 female adolescents were investigated. On average, Cmax
was 6.72 ng/mL and occurred at 1.43 h after dosing. With
a mean 9.5% contribution from extrapolation, average
AUC0–∞ was 86.1 ng h/mL. Mean CL/F was 145 ml/minand mean V/F was 267 L (Table 2). However, the data from
an adult study (304 levonorgestrel plasma concentrations in
16 women) were also reconsidered. Adolescents had a
mean levonorgestrel Cmax that was almost half of that de-
tected in adults, with a mean ratio of 0.53 and a 90% CI
(Table 2). The difference among the groups with respect to
AUC0–∞ was of borderline significance, with a mean ratio
of 0.77. Also, the variance between the treatment groups
with respect to CL/F was marginally significant, with a
mean ratio of 1.31.
In addition, a group of investigators studied the
pharmacokinetics of levonorgestrel where compared
dosages were two 0.75 mg doses taken 12 h apart, two
0.75 mg doses taken 24 h apart, and a single 1.5 mg dose
[23]. In this trial, five women were randomized to be
given all three treatments. They also received a four
week washout period between the treatments. tmax was
estimated 1.5–1.8 h after each of the two 0.75 mg doses
and 2.6 h after the single 1.5 mg dose. Cmax after the
1.5 mg single dose was about 50% greater than those
after each 0.75 mg dose. The second dose of both the 12
and 24 h double dose regimens revealed a slightly higher
Cmax than that of the first dose. All three groups had
similar mean LNG concentrations at 48 h.
For finding an acceptable levonorgestrel regimen for
emergency contraception, a two-dose regimen 0.75 mg
levonorgestrel 12 h apart and a single dose 1.5 mg levo-
norgestrel were studied in 1118 Nigerian women [30].
Eleven pregnancies were reported, among them 7 were
in the two-dose group and 4 in the single dose group.
The relative risk of pregnancies was similar in both
groups. Also, the estimated success rate of 86.80% in the
0.75 mg group was significantly lower than the 92.99%
for the 1.5 mg group (Table 3). Minor side effects were
reported such as nausea, vomiting, menorrhagia, lower
abdominal pains, headache, breast tenderness and dizzi-
ness. Considerably more women who were in the high-
dose group reported headache, breast tenderness and
heavy menstrual flow.
Another study considering the same dosage regimen
among 3022 Nigerian women revealed similar effective-
ness between the treatment groups. In the two-dose
regimen, post-treatment pregnancy proportions were
0.57% whereas in the single-dose regimen, the propor-
tion was 0.64% (Table 3). Most of the women menstru-
ated in the first day of expected menses and the groups
did not diverge regarding reported side effects. In gen-
eral, the most common adverse event was nausea, which
was accounted for about 22% of participants in both
groups. Some of the participants also experienced fa-
tigue, dizziness, headache, breast tenderness and lower
abdominal pain [31].
A different study compared the efficacy of two doses
of 0.75 mg levonorgestrel among 2071 Chinese women,
Table 2 Pharmacokinetic comparison of different dosage regimens of levonorgestrel











tmax (h) Kel (1/h) t1/2 (h)
Gainer et al., (2007) [28] 1.5 mg 28.6 45.0 252.8 262.6 15.4 2.0 —— 29.3 ——
Johansson et al., (2002) [23] 0.75 mg & 1.5 mg A:49.9 A:81.3 A:139.5 —— A:7.9 A:1.8 —— A:43.7 Nausea, sleepiness, headache.
B:51.9 B:73.2 B:136.0 B:8.4 B:1.4 B:32.0
C:88.8 C:130.8 C:290.9 C:12.4 C:2.5 C:43.3
Kook et al., (2002) [24] 0.75 mg —— —— 111.8 123.1 14.1 1.63 0.030 24.4 Menstrual irregularity
Sambol et al., (2006) [29] 0.75 mg —— —— —— 86.1 6.72 1.43 —— 21.2 Headaches, dizziness, nausea, cramps
Tremblay et al., (2001) [25] 0.75 mg —— —— —— 133.02 —— 2.27 0.042 21.72 ——
AUC0-t: Area under the plasma concentration time curve calculated by the trapezoidal rule from time 0 until the last time point.
AUC0-∞: Area under the plasma concentration time curve corrected for the previous administration and extrapolated to infinity.
A: One tablet of 0.75 mg levonorgestrel at time −12 h and one tablet at time 0.
B: One tablet of 0.75 mg levonorgestrel at time 0.




















Table 3 Clinical statistics of levonorgestrel
Outcome measures Dosage regimen
1.5 mg 0.75 mg (12 hourly) 0.75 mg (24 hourly)
Pregnancy rate (%) 0.64(a) – 1.28(b) 0.57(b) – 2.0(c) 1.9(c)




heavy menses, fatigue, vomiting
Nausea, diarrhea, lower abdominal
pain, delay of menses
Dizziness
(a) [30]; (b) [31]; (c) [32].
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period extended to 120 h after unprotected coitus [32].
The crude pregnancy rate was 2.0% in the 12 h group
and 1.9% in the 24 h group. The prevented fraction of
pregnancies was considered to be 75% in the 12 h group
and 72% in the 24 h group (Table 3). The effectiveness
of the 12 h regimen dropped significantly when there
were further acts of coitus after treatment which was
not observed in the 24 h group. The overall side-effects
were mild and tolerable. Nausea and vomiting occurred
in 10% of women whereas diarrhea and breast tender-
ness was significantly more common in the 12 h group.
Also, the timing of menses did not vary between the two
regimens.
A randomized, double-blind, placebo-controlled study
evaluated to what degree the usual dose of levonorges-
trel or a single dose, given in the follicular phase, affects
the ovulatory process during the subsequent period of
five days [33]. Time of treatment was determined by the
diameter of the dominant follicle. Every woman had
equivalent diameter allocated for all her treatments. Fol-
licular rupture failed to take place during the five day
period in 44%, 50% and 36% of cycles respectively with
the standard, single dose and placebo. Ovulatory dys-
function occurred in 35%, 36% and 5% of standard,
single dose or placebo cycles, respectively, which is char-
acterized by follicular rupture associated with absent,
blunted or untimely gonadotropin surge.
Durand M et al. [18] studied the effects of short-term
administration of levonorgestrel at different phases of
the ovarian cycle on the pituitary-ovarian axis, corpus
luteum function and endometrium. The participants
were studied during two menstrual cycles. Transvaginal
ultrasound and serum LH were performed in both cycles
from the detection of urinary LH until ovulation. During
the complete luteal phase, serum estradiol and proges-
terone were measured. An endometrial biopsy was also
taken, which revealed the endometrial histology as nor-
mal in all ovulatory-treated cycles. Finally, they sug-
gested that “intervention of LNG with the mechanisms
initiating the LH preovulatory surge depends on the
stage of follicle growth”. Thus, anovulation caused from
disrupting the regular development and/or the hormonalactivity of the developing follicle, only when LNG was
given in the preovulatory phase.
Durand M et al. [34] analyzed endometrial expression
and serum glycodelin concentrations during the luteal
phase following oral levonorgestrel at various stages of
the ovarian cycle. All the participants were studied dur-
ing two consecutive cycles, namely a control cycle and
the treatment cycle. During the luteal phase, serum pro-
gesterone and glycodelin were measured daily and an
endometrial biopsy was taken for immuno-histochemical
glycodelin-A staining. Levonorgestrel altered the luteal
phase secretory pattern of glycodelin in serum and
endometrium. The results accounted for the action of
LNG in EC in those women who take LNG before the
LH surge, based on the potent gamete adhesion inhibi-
tory activity of glycodelin-A.
In a different study, 0.75 mg LNG was administered
twice right before ovulation, to test whether LNG acts
as an emergency contraceptive by stopping the pre-
ovulatory LH surge and thereby delaying ovulation [19].
LNG was taken by twelve women on or before the day
of the first significant increase in urinary LH in 12 cycles.
The LH peak and the onset of next menses were delayed
(16.8 days) in 30% participants. Despite a normal LH
peak and cycle length, one woman did not ovulate at all.
LNG did not affect ovulation or the cycle length in the
remaining eight participants, but the length of the luteal
phase and the total luteal phase LH concentrations were
considerably reduced.
Noé G et al. [35] aimed to evaluate whether levonor-
gestrel administered after ovulation is equally effective
to LNG administered before ovulation. Blood samples
were taken for analysis of LH, estradiol and progesterone
concentrations on the day of LNG administration and
during five days’ follow-up. Vaginal ultrasound analyses
were also done for size of the leading follicle and/or cor-
pus luteum. 122 women among the total of 388 women
had coitus on fertile cycle days according to ultrasound
and endocrine findings. 87 women were in days −5
to −1 and 35 women were in day 0 or beyond at the
time of LNG intake. Estimated numbers of pregnancies
among the 87 and 35 women were 13 and 7 respectively,
while actually 0 and 6 pregnancies respectively occurred.
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gestrel in a single dose was also examined [36]. The ob-
served bleeding patterns after treatment were compared
with usual patterns reported by the participants and with
patterns observed in a previous study on women who
had not taken any emergency contraceptives. Treatment
in the first three weeks of the menstrual cycle signifi-
cantly reduced that cycle as compared with both the
usual cycle length and with the cycle duration in a com-
parison group. The magnitude of this outcome was
greater if the pills were taken earlier. Additionally, the
duration of the first menstrual period after treatment in-
creased significantly with cycle week of treatment. This
timeline was longer in participants who used the treat-
ment than in those who did not.
Discussion
From the pharmacokinetic perspective, levonorgestrel
was rapidly absorbed after either one single or two ad-
ministrations at a 12 or 24 h time interval of levonorges-
trel 750 μg oral tablets. Also, the ADME profiles of
levonorgestrel following the three different treatment
regimens were similar [25]. The blood levels following
administration of the first of two tablets (at 12 h inter-
val) in the emergency contraceptive regimen were main-
tained for a sufficiently long period of time to prevent
further unwanted fertilization [24]. Nevertheless, levo-
norgestrel was generally well tolerated by adolescents
(single dose, 0.75 mg). The differences in observed total
concentration were not likely to be seen in the unbound
concentration. So, there is no reason based on pharma-
cokinetic data to expect that adolescents will experience
greater adverse effects or lesser therapeutic effects after
administration of the usual dose of LNG EC [29].
The AUC after administration of one single dose of
1.5 mg LNG was greater than two doses of 0.75 mg with
a 12 or 24 h interval. Therefore, the administration of a
single larger dose was more effective than the same
amount of LNG divided into two doses [23]. On the
other hand, nursing mothers might need EC but when a
medication is taken by nursing women, the risks and
benefits of taking that drug must first be weighed. Since
LNG passes rapidly into the milk (single dose, 1.5 mg),
the period of maximum LNG excretion in milk should
be avoided and nursing should be discontinued and milk
discarded for an interval of at least 8 h, but not longer
than 24 h, after the use of EC [28].
From clinical point of view, the single 1.5 mg regimen
of levonorgestrel appeared more effective than the split
doses of 0.75 mg taken twice 12 h apart, not in terms of
raw pregnancy rate or relative risk but in terms of effect-
iveness rate. The earlier each regimen was given after
unprotected sexual intercourse, the more was the effi-
cacy [30]. However, some authors claimed that theregimen of single-dose levonorgestrel was non-inferior
and as well tolerated as the two-dose regimen. The pa-
tients requested EC did so because they were not using
contraception at coitus. So it was suggested that levo-
norgestrel EC should be offered up to 5 days after un-
protected intercourse [31]. In case of a 0.75 mg regimen,
the 24 h double dose levonorgestrel regimen was as ef-
fective as the 12 h regimen for emergency contraception
up to 120 h after unprotected intercourse [32]. All the
treatment regimens were well tolerated except some
common side-effects and did not have any lasting effect
on the individuals.
While assessing the mode of action of levonorgestrel,
it was observed that LNG used for EC prevents preg-
nancy primarily by interfering with the ovulatory process
and method failures are most likely due to treatment
given too late to effect such intervention. No association
was found between the usage of LNG and the risk of
pregnancy complications, major congenital malforma-
tions or any other adverse pregnancy outcomes in case
of its failure as an emergency contraceptive [37,38]. In
addition, single administration of 0.75 mg LNG was at
least as effective as the standard two-dose regimen
for inhibiting ovulation [33]. However, preovulatory
administration of LNG suppresses ovulation in most
but not all cases. Hinderance of LNG with the mecha-
nisms involved in initiating the Luteinizing hormone
preovulatory surge depends on the stage of follicular de-
velopment. Thus, anovulation results from disrupting
both normal maturation and hormonal natural action of
a growing follicle [18]. Other plausible mechanism of ac-
tions of LNG such as retardation of the endometrium,
interfering with sperm motility and changing cervical
mucus [19]. This is because the in vitro effect of LNG as
EC on sperm fertilizing capacity and embryo develop-
ment remains poorly understood in various other poten-
tial studies [39-41].
Hormonal EC with LNG can alter endometrial glyco-
delin secretion in two important phases of the cycle
when taken before the LH surge [42]. The first is during
the fertile window and the second is the phase of uterine
receptivity, both of which are of interest because of their
antifertility activity [34]. However, it was observed that
neither the glycodein level nor the proportion of
motile sperm and cervical mucus is influenced by LNG
[43]. Also, emergency contraception of levonorgestrel
(1.5 mg) in a single dose taken in the first 3 weeks of the
menstrual cycle shortened that cycle. The degree of this
effect was higher than the earlier the pills were taken.
This regimen taken later in the cycle had no effect on
cycle length but caused prolongation of the next
menstrual episode [36]. So it is important to note that,
LNG-EC is very effective in preventing pregnancy when
it is administered before ovulation, but it is ineffective in
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LNG-EC is less effective than regular contraceptives
and its use should be controlled to emergency sit-
uations [35].
Limitations
The quality of several reports was poor. A number of re-
ports lacked details about the study procedures, including
the inclusion criteria, frequency of follow-up contacts, or
method of pregnancy ascertainment. Seven reports did not
specify the intended duration of follow-up, although five of
these did present detailed information about continuation,
discontinuation, and loss to follow-up in each month or
3 month period. Some studies did not mention the propor-
tion of participants who may have continued to use the
method after the last follow-up visit and who therefore may
have had pregnancies that occurred during method use but
that were not ascertained by the researchers. Studies were
not able to explore the possibility that prevention of preg-
nancy may occur by some other natural means rather than
effect of drug. We could not determine whether these
shortcomings were the result of poor study quality or sim-
ply inadequate reporting. However, several studies that pro-
vided more than two thirds of the data in this review were
well designed and clearly reported.
Conclusions
For emergency contraception, the US-FDA approves two
doses of levonorgestrel 0.75 mg. The first dose should be
taken within 72 h of unprotected intercourse and the sec-
ond dosage, 12 h after the initial dosage. On the other hand,
a single dose of levonorgestrel 1.5 mg is also safe and effect-
ive for emergency contraception. Based on previous
research findings, pharmacokinetic data and patient out-
comes; the single dose strategy is warranted. Additionally,
in case of two doses of levonorgestrel 0.75 mg, the second
dosage can be taken within 24 h after the first dosage and
the effectiveness of the drug would not be compromised.
The clinical significance of this information is critical for
clinicians instructing patients or prescribing levonorgestrel
for emergency contraception.
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